ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Together, these findings highlight xanthohumol as a natural compound capable of targeting BCR-ABL-driven leukemic cells via multiple mechanisms and support its further investigation as a potential adjunct in CML therapy.